ARTICLE | Distillery Therapeutics


August 22, 2017 7:13 PM UTC

Patient sample and mouse studies suggest inhibiting G-CSF alone or in combination with Gemzar gemcitabine could help treat pancreatic ductal adenocarcinoma (PDAC). In patient samples, levels of G-CSF were higher in the tumor epithelium than in matched normal tissues. In a mouse model of PDAC, knockdown of G-CSF decreased tumor growth compared with normal G-CSF expression, and Gemzar plus an anti-G-CSF antibody decreased tumor growth compared with either agent alone. Next steps could include identifying and testing G-CSF inhibitors in PDAC models...